Form 4: Insider Sells CYPH Shares Amid Fund Liquidation

A director and officer of Cypherpunk Technologies Inc. reported significant sales of common stock by affiliated entities as part of their liquidation process.

Summary

• Douglas E. Onsi, a Director, 10% Owner, CEO, CFO, President, General Counsel, Treasurer, and Secretary of Cypherpunk Technologies Inc. (CYPH), reported transactions.
• On November 17, 2025, HCV VIII Liquidating Trust sold 261,840 shares of CYPH common stock at a weighted average price of $3.14 per share.
• On the same date, HealthCare Ventures IX, L.P. (HCV IX) sold 414,479 shares of CYPH common stock at a weighted average price of $3.14 per share.
• These sales were part of liquidating distributions due to the wind-up and liquidation of HCV VIII Liquidating Trust and HCV IX.
• The sales occurred in multiple transactions with prices ranging from $2.40 to $3.40 per share.
• Following these transactions, Onsi directly owns 106,146 shares and indirectly owns 2,136 shares through Nine Capital Partners.
• Onsi disclaims beneficial ownership of the sold shares and those held by Nine Capital Partners, except to the extent of his proportionate pecuniary interest.

Sentiment

Score: 3

Explanation: The filing reports significant sales of company stock by entities affiliated with a key executive and director. While the reason is stated as fund liquidation, such large sales are generally perceived negatively by the market as they represent a reduction in holdings by informed parties and can exert downward pressure on the stock price.

Negatives

• Significant insider-affiliated selling of 676,319 shares of common stock.
• The sales are driven by the liquidation of investment entities, which could indicate a reduction in institutional support or a lack of future investment interest from these specific funds.

Risks

• Large sales by affiliated entities could put downward pressure on the stock price.
• The liquidation of investment vehicles (HCV VIII Liquidating Trust and HealthCare Ventures IX, L.P.) that previously held significant stakes in Cypherpunk Technologies Inc. might signal a reduction in institutional confidence or a shift in investment strategy by these specific funds.

Future Outlook

NA

Management Comments

• The reporting person undertakes to provide to the Issuer, any security holders of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth in this Form 4.
• The reporting person disclaims beneficial ownership of such shares of common stock held by Nine Capital Partners, and sold by each of HCV IX and the HCV Liquidating Trust, except to the extent of the reporting person's proportionate pecuniary interest therein.

Industry Context

NA

Related Party Transactions

• Sales of 261,840 shares by HCV VIII Liquidating Trust, where Douglas E. Onsi is a beneficiary.
• Sales of 414,479 shares by HealthCare Ventures IX, L.P., where Douglas E. Onsi is a Managing Director of its General Partner.

Stakeholder Impact

• Shareholders: Potential for increased selling pressure on the stock, which could negatively impact share price. May raise questions about institutional confidence, even if the reason is fund liquidation.

Key Dates

Recommendation

The significant sales by affiliated entities, totaling 676,319 shares, are a notable event. While the stated reason is the liquidation of investment funds, which is an external factor, such a large volume of shares entering the market can create downward pressure on the stock price. Investors should monitor the stock's performance and consider the implications of reduced institutional holdings. A 'hold' recommendation is appropriate to observe market reaction and any further developments, as the sales are not directly indicative of operational issues but rather a change in ownership structure from specific funds.

Keywords

Cypherpunk Technologies, CYPH, Form 4, Insider Trading, Stock Sale, Beneficial Ownership, Liquidation, HCV VIII Liquidating Trust, HealthCare Ventures IX, Douglas E. Onsi